Rigel announces VEPPANU availability for ER+/HER2- ESR1-mutated breast cancer
Rigel (RIGL) says VEPPANU™ (vepdegestrant) is now available for patients with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.